Artios Pharma’s £65m Series B To Spur Development Of DDR Cancer Therapies

LSX article on Artios following our recent £65 million Series B fundraise and having being shortlisted in the EU Private Finance Raise of the Year (>£30m) category and also the EU Private Company of the Year category at this year’s Lifestars Awards 2018. This follows a double win at LSX’s Biotech and Money Awards 2017.

“LSX caught up with Niall Martin, Chief Executive Officer, and Nick Staples, Chief Business Officer, to learn more about the finance raise, the advance of the company’s pipeline, and developments in the DDR space…”

Artios Pharma’s £65m Series B To Spur Development Of DDR Cancer Therapies

 

View all news